RF 1012

Drug Profile

RF 1012

Latest Information Update: 17 Jan 2007

Price : $50

At a glance

  • Originator SuperGen
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological disorders

Most Recent Events

  • 17 Jan 2007 Discontinued - Phase-I/II for Chemoprotection and Radioprotection in USA (unspecified route)
  • 17 Jan 2007 Discontinued - Phase-I/II for Haematological disorders (Chemotherapy-induced, Radiation-induced, Prevention) in USA (unspecified route)
  • 08 Jan 2001 No-Development-Reported for Haematological disorders (Chemotherapy-induced, Radiation-induced, Prevention) in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top